DM
ATXS

Deerfield Management’s Astria Therapeutics ATXS Stock Holding History

Deerfield Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,153
Closed -$134K – 141
2024
Q3 		$134K Buy
+12,153
New +$135K ﹤0.01% 433
2017
Q1 		– Sell
-11,382
Closed -$2.46M – 107
2016
Q4 		$2.46M Sell
11,382
-8
-0.1% -$1.96K 0.1% 89
2016
Q3 		$4.21M Buy
11,390
+664
+6% +$175K 0.2% 64
2016
Q2 		$2.38M Hold
10,726
– – 0.09% 85
2016
Q1 		$3.24M Hold
10,726
– – 0.14% 82
2015
Q4 		$5.1M Buy
10,726
+251
+2% +$120K 0.21% 83
2015
Q3 		$5.08M Sell
10,475
-1,826
-15% -$1.3M 0.2% 88
2015
Q2 		$9.01M Buy
+12,301
New +$9.3M 0.3% 73

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Deerfield Management's ATXS Position: Q4 2024 in Review

Deerfield Management sold out of Astria Therapeutics (ATXS) in Q4 2024, closing a stake of 12,153 shares — an estimated $134K sold.

Deerfield Management first reported a position in ATXS in Q2 2015 and held it in 8 quarters. The position peaked at $9.01M in Q2 2015. 110 funds tracked by Wall St. Rank hold ATXS as of Q4 2024.

  • Deerfield Management reported no remaining Astria Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Deerfield Management sold 12,153 Astria Therapeutics shares in Q4 2024, an estimated $134K.
  • Deerfield Management first reported a position in Astria Therapeutics in Q2 2015 and held it in 8 quarters.
  • Deerfield Management's Astria Therapeutics position peaked at $9.01M in Q2 2015.
  • 110 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2024.

Based on Deerfield Management's 13F filing for Q4 2024, filed 14 Feb 2025.